Related Experiment Video
Updated: Sep 5, 2025

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Empiric Antibiotics in COVID 19: A Narrative Review
1Internal Medicine, Presbyterian Hospital, Albuquerque, USA.
Abstract:
Coronavirus disease 2019 (COVID-19) is a febrile respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It may develop into respiratory failure or pneumonia. Antimicrobials have facilitated medical progress for decades. However, antimicrobial resistance (AMR) limits our ability to treat diseases and undermines efforts to attain health-related sustainable development and universal health coverage objectives. Antimicrobial resistance is a major concern that must be addressed immediately. The principles of appropriate prescription, optimal use of antimicrobials, quality diagnosis and treatment, and infection reduction and prevention have led to antimicrobial stewardship initiatives. During the current COVID-19 epidemic, there are possible hazards to antimicrobial stewardship measures and drug resistance. Many people with mild illnesses but without pneumonia or moderate infections with pneumonia are administered antibiotics. Antimicrobial therapy has no documented benefit in COVID-19 patients without microbial co-infection. COVID-19 patients may have an increased risk of developing concomitant microbial infections, which would necessitate antibiotic treatment. This review evaluated the role of empiric antibiotics in COVID-19 patients.
Insights
Antimicrobial stewardship is crucial during COVID-19 to combat resistance. This review examines the appropriate use of antibiotics in COVID-19 patients, especially concerning co-infections.
Area of Science:
- Infectious Diseases
- Public Health
- Pharmacology
Background:
- Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is a significant global health threat.
- Antimicrobial resistance (AMR) is a growing concern, jeopardizing medical progress and sustainable development goals.
- Antimicrobial stewardship programs aim to optimize antimicrobial use and prevent resistance.
Purpose of the Study:
- To evaluate the role and impact of empiric antibiotic use in COVID-19 patients.
- To assess potential risks to antimicrobial stewardship during the COVID-19 pandemic.
- To determine the necessity of antibiotics in COVID-19 management.
Main Methods:
- Literature review of studies on antibiotic use in COVID-19.
- Analysis of data regarding co-infections in COVID-19 patients.
- Evaluation of antimicrobial stewardship principles in the context of the pandemic.
Main Results:
- Antibiotics are frequently administered to COVID-19 patients, even those with mild illness or without pneumonia.
- Antimicrobial therapy offers no documented benefit for COVID-19 patients lacking microbial co-infections.
- COVID-19 patients may face an increased risk of secondary microbial infections requiring antibiotic treatment.
Conclusions:
- Judicious use of antibiotics is essential in COVID-19 management to preserve antimicrobial efficacy.
- Antimicrobial stewardship efforts must be maintained and adapted during pandemics.
- Further research is needed to guide antibiotic prescribing for COVID-19 patients with potential co-infections.
More Related Videos
Related Concept Videos
Antimicrobial Effectiveness
Acute Pyelonephritis II: Diagnostic Studies and Management
Development of Antibiotic Resistance
Antibiotic Selection
Urine Studies II: Urine Culture and Sensitivity Test
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

